Tag Archives: myl

Teva’s Auspex Buyout Pays, But Mylan Bid Hits Snag

Israeli drug giant Teva Pharmaceutical Industries (TEVA) reported positive results for a recently acquired drug Tuesday. Teva stock was down a fraction, however, as the company also faced a new roadblock in its effort to take over Mylan (MYL). Teva said that SD-809, a drug that it had gained in its $3.5 billion buyout of Auspex Pharmaceuticals last month, hit the primary endpoint in a pivotal trial of tardive dyskinesia, a movement disorder that

Will Perrigo’s Glaxo Buy Make It Too Pricey?

Embattled generic drugmaker Perrigo (PRGO) agreed to buy a portfolio of over-the-counter drugs from GlaxoSmithKline (GSK) Tuesday, in a move some interpreted as helping it fend off the advances of Mylan (MYL). For an undisclosed sum, Perrigo agreed to acquire a variety of products including cold and flu medicines, nicotine patches and cold-sore treatments, whose sales totaled $110 million last year largely in European markets. Glaxo, for its part,

Mylan Q1 Mixed; Abiomed, Mallinckrodt, Zoetis Beat

Generic-drug giant Mylan delivered a mixed first-quarter report late Tuesday after three other top-rated medical stocks issued more positive reports earlier in the day. Its shares slipped a fraction in after-hours trading. Mylan’s (MYL) profit rose 6% over the year-earlier quarter to 70 cents a share, beating analysts’ consensus by a penny, according to Thomson Reuters. Sales increased 9% to $1.87 billion, missing Wall Street’s number by around